Aclaris Therapeutics, Inc.
ACRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -40.1% | 5% | 340.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 85.1% | 42.1% | 59.8% | 30.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -276.3% | -369.5% | -283.5% | -953.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -705.5% | -283.1% | -292.1% | -1,344% |
| EPS Diluted | -1.71 | -1.27 | -1.33 | -1.6 |
| % Growth | -34.6% | 4.5% | 16.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |